Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $50.00 at HC Wainwright

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective cut by HC Wainwright from $60.00 to $50.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on RARE. Truist Financial cut their price target on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Leerink Partners lowered their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Guggenheim cut their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 21st. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.18.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $20.18 on Tuesday. The stock’s fifty day simple moving average is $26.27 and its 200 day simple moving average is $29.66. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $45.00. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -3.46 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.00 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.39) earnings per share. On average, research analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,061 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at approximately $2,095,308.60. This trade represents a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 6,227 shares of company stock worth $187,126 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Ultragenyx Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock valued at $236,068,000 after purchasing an additional 131,087 shares in the last quarter. State Street Corp increased its holdings in Ultragenyx Pharmaceutical by 16.5% in the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after buying an additional 610,559 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after buying an additional 1,864,164 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company’s stock worth $58,509,000 after acquiring an additional 73,309 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 16.3% during the 4th quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after acquiring an additional 257,701 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on RARE while lowering its price target from $60 to $50, signaling continued analyst conviction in the company’s upside despite the cut. HC Wainwright lowers PT but maintains Buy
• Positive Sentiment: Coverage pieces highlight Ultragenyx’s strong rare-disease pipeline and sizable upside potential, reinforcing longer-term bullish views that may attract investors focused on pipeline value. Pipeline-driven bullish coverage
• Neutral Sentiment: Wedbush reaffirmed a Neutral rating with a $25 price target, suggesting some analysts see limited near-term catalysts while others remain constructive — this creates mixed signals for traders. Wedbush reaffirms Neutral
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors to join a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering purchases from Aug 3, 2023 to Dec 26, 2025; the lead-plaintiff deadline is April 6, 2026 — this legal overhang can pressure the stock and increase perceived risk. KSF class action notice Rosen Law Firm notice Schall Law Firm notice Robbins Geller notice Kessler Topaz complaint Faruqi & Faruqi reminder
• Negative Sentiment: Ultragenyx announced a roughly 10% workforce reduction as it targets profitability in 2027; while cost cuts could improve longer-term margins, layoffs and execution risk typically weigh on near-term sentiment. Workforce reduction announcement

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.